A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19
Latest Information Update: 26 Jul 2022
At a glance
- Drugs Clevudine (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Bukwang Pharmaceutical
Most Recent Events
- 20 Jul 2022 Status changed from recruiting to completed.
- 25 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.
- 25 Jan 2021 Planned primary completion date changed from 30 Sep 2020 to 30 Jan 2021.